Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Van ECK Associates Corp

Van ECK Associates Corp decreased its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 13.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,615,695 shares of the company’s stock after selling 259,692 shares during the quarter. Van ECK Associates Corp owned approximately 0.14% of Teva Pharmaceutical Industries worth $35,610,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of TEVA. FMR LLC raised its stake in Teva Pharmaceutical Industries by 49.5% during the third quarter. FMR LLC now owns 62,740,763 shares of the company’s stock worth $1,130,589,000 after acquiring an additional 20,762,226 shares during the period. Janus Henderson Group PLC grew its position in Teva Pharmaceutical Industries by 7,945.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,791,937 shares of the company’s stock worth $86,350,000 after purchasing an additional 4,732,374 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Teva Pharmaceutical Industries by 237.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,377,517 shares of the company’s stock worth $60,863,000 after purchasing an additional 2,376,668 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd grew its position in Teva Pharmaceutical Industries by 6.8% in the 3rd quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company’s stock worth $621,337,000 after purchasing an additional 2,204,623 shares during the last quarter. Finally, State Street Corp grew its position in Teva Pharmaceutical Industries by 10.0% in the 3rd quarter. State Street Corp now owns 19,500,683 shares of the company’s stock worth $351,402,000 after purchasing an additional 1,778,268 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Roberto Mignone sold 286,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Trading Down 2.4 %

Teva Pharmaceutical Industries stock opened at $16.24 on Friday. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.61 and a current ratio of 0.98. The firm has a market cap of $18.39 billion, a price-to-earnings ratio of -11.20, a price-to-earnings-growth ratio of 1.39 and a beta of 0.71. Teva Pharmaceutical Industries Limited has a 1 year low of $12.51 and a 1 year high of $22.80. The firm’s 50 day moving average price is $19.98 and its two-hundred day moving average price is $18.49.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, research analysts predict that Teva Pharmaceutical Industries Limited will post 2.62 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on the stock. UBS Group decreased their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Piper Sandler upped their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. JPMorgan Chase & Co. upped their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. Barclays decreased their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. Finally, StockNews.com cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and an average target price of $23.57.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.